These cash runways assume ENTA partners the RSV phase 3, correct. Seven months after phase 2 results and it hasn’t happened. Going it alone would shorten it by some number of quarters. They could shelve it I guess, but I don’t see that happening.
The US patent on Glecaprevir’s crystal formulations (9,321,807) runs until 12/5/2035. As far as I know, this is the longest-running patent relevant to Mavyret sales in the US. Patents that ABBV licensed from ENTA in some other countries may expire later.